Alteon® HA Femoral Hip Stem Rounds Out Big Week of First Surgeries for Exactech
June 12 2017 - 10:37AM
Business Wire
Exactech (Nasdaq: EXAC), a developer and producer of bone and
joint restoration products and biologic solutions for extremities,
knee and hip, announced that the first surgeries using the new
Alteon® HA Femoral Hip Stem took place last week. The total hip
replacements were performed by implant design team members Joseph
Locker, MD, of The Orthopaedic Institute in Ocala, Fla. and Sam
Sydney, MD, of Orthopaedic Associates of Central Maryland in
Baltimore. This marks Exactech’s fourth orthopaedic innovation in a
week to debut in U.S. operating rooms.
Locker implanted the Alteon HA Stem using a direct anterior
approach. “It had the feel and ease of insertion of a proximal
wedge, but with the stability of a tri-taper fully coated
hydroxyapatite stem,” he said. Sydney shared his satisfaction with
the “well engineered instruments and excellent feel of the implant
upon final seating.”
The fully hydroxyapatite (HA) coated prosthesis, with its
incremental stem sizing and proportional neck lengths, features
design and surgical technique principles based on more than 25
years of clinical success.1 The HA Femoral Stem is designed to
provide initial stability and long-term biologic fixation while
providing surgeons a simple, broach-only system that offers
flexibility to accommodate various surgical approaches.
The HA Femoral Stem is the latest addition to the Alteon product
family which also includes the Tapered Wedge Femoral Stem, Neck
Preserving Stem and newly released Monobloc Revision Stem. Each of
the Alteon stems uses the same core femoral instruments, therefore
improving O.R. efficiency.
“Exactech is coming off a phenomenal week of first surgeries,
with the Alteon HA Stem being one of four new products to make its
clinical debut. The HA Stem enhances Exactech’s robust portfolio of
hip products by providing surgeons additional options for creating
stable and reproducible femoral reconstructions,” said Edmund
Loftus, Director of Engineering and Development and Hip Business
Unit leader. “This past week speaks to the caliber of our surgeon
and engineering design teams at Exactech, as well as everyone who
works to make these surgeries happen.”
In each of these cases, the HA Femoral Stem was coupled with the
InteGrip® Cup, an acetabular shell comprised of three-dimensional,
porous ingrowth material, that was developed to improve initial
stability and long-term fixation of the acetabular prosthesis.
Full U.S. market availability for the Alteon HA Stem is planned
for the beginning of 2018.
1 Vidalain JP. Twenty-year results of the cementless Corail
stem. Int Orthop. 2011 Feb;35(2):189-94.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech can be found
at http://www.exac.com.
A current investment profile on Exactech (Nasdaq: EXAC) is
available online at http://www.hawkassociates.com/profile/exac.cfm.
To receive future releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170612005771/en/
Exactech Inc.Investor contactsJody Phillips,
352-377-1140Executive Vice President of Finance & Chief
Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins,
305-451-1888EXAC@hawkassociates.comorExactechMedia
contactsPriscilla Bennett, 352-377-1140Vice President, Corporate
& Marketing Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2023 to Apr 2024